News

Press ReleaseCell and gene therapy industry continues to expand manufacturing infrastructure in the UK
Filter:AllGeneralRegulatory NewsNewsletterExternalManufacturingPress ReleaseSkills and TrainingChallenge Theme – PATChallenge Theme – AAVChallenge Theme – iPSCsNon ClinicalCommercialisation of Research
Year:All2024202320222021 →
ReNeuron wins major UK grant to advance its exosome nanomedicine platformReNeuron wins major UK grant to advance its exosome nanomedicine platformSynpromics and Cell Therapy Catapult collaborate to develop novel large scale viral vector manufacturing platform based on stable producer cell linesSynpromics and Cell Therapy Catapult collaborate to develop novel large scale viral vector manufacturing platform based on stable producer cell linesCell Therapy Catapult, University of Birmingham and Cancer Research Technology launch new collaboration for CAR-T cell immuno-oncology therapy developmentCell Therapy Catapult, University of Birmingham and Cancer Research Technology launch new collaboration for CAR-T cell immuno-oncology therapy developmentHorizon 2020 awards €6.8m to TETRA consortium for pivotal replacement trachea trialHorizon 2020 awards €6.8m to TETRA consortium for pivotal replacement trachea trialCell Therapy Catapult details key milestones and achievements in 2015 Annual ReviewCell Therapy Catapult details key milestones and achievements in 2015 Annual ReviewCell Therapy Catapult signs Memorandum of Understanding with Kanagawa Prefecture, JapanCell Therapy Catapult signs Memorandum of Understanding with Kanagawa Prefecture, JapanBIA publishes briefing paper on ATMPs and regenerative medicineBIA publishes briefing paper on ATMPs and regenerative medicineEMA releases new guidance on methods to be used in the design and conduct of post-authorisation efficacy studiesEMA releases new guidance on methods to be used in the design and conduct of post-authorisation efficacy studiesConstruction initiated on Cell Therapy Catapult’s £55 million cell and gene therapy manufacturing centreConstruction initiated on Cell Therapy Catapult’s £55 million cell and gene therapy manufacturing centreUS Guidance for Industry updateUS Guidance for Industry updateEMA implements new system for better reporting of suspected adverse reactions to medicines via EudraVigilanceEMA implements new system for better reporting of suspected adverse reactions to medicines via EudraVigilanceEMA continues its efforts to facilitate early patient access to innovative medicines through initiation of PRIME schemeEMA continues its efforts to facilitate early patient access to innovative medicines through initiation of PRIME scheme